ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 791,79
0,64%
Dow Jones
42 339,36
0,39%
DAX
19 473,63
1,32%
Brent Oil
71,775
1,16%
Bitcoin
65 723,60
0,83%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PAVmed Inc (PAVM)

  7. PAVmed Inc (PAVM) Actualités

PAVM

PAVmed (PAVM)

PAVmed Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PAVM
DateHeureSourceTitreSymboleSociété
24/09/202414h01PR Newswire (US)American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestNASDAQ:PAVMPAVmed Inc
16/09/202422h30PR Newswire (US)PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing RequirementsNASDAQ:PAVMPAVmed Inc
10/09/202413h56PR Newswire (US)Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressNASDAQ:PAVMPAVmed Inc
03/09/202413h51PR Newswire (US)Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthNASDAQ:PAVMPAVmed Inc
20/08/202414h16PR Newswire (US)Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and CancerNASDAQ:PAVMPAVmed Inc
13/08/202414h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PAVMPAVmed Inc
13/08/202414h16PR Newswire (US)The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal CancerNASDAQ:PAVMPAVmed Inc
13/08/202414h01PR Newswire (US)PAVmed Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
12/08/202422h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PAVMPAVmed Inc
12/08/202414h07PR Newswire (US)Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/08/202414h31PR Newswire (US)Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing EventNASDAQ:PAVMPAVmed Inc
06/08/202414h15PR Newswire (US)Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
05/08/202414h15PR Newswire (US)Lucid Diagnostics to Participate in Upcoming Investor ConferencesNASDAQ:PAVMPAVmed Inc
30/07/202414h15PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024NASDAQ:PAVMPAVmed Inc
29/07/202414h15PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024NASDAQ:PAVMPAVmed Inc
23/07/202414h01PR Newswire (US)Lucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeNASDAQ:PAVMPAVmed Inc
11/07/202414h31PR Newswire (US)Lucid Diagnostics Launches New Corporate WebsiteNASDAQ:PAVMPAVmed Inc
02/07/202413h55PR Newswire (US)Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationNASDAQ:PAVMPAVmed Inc
13/06/202413h58PR Newswire (US)PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteNASDAQ:PAVMPAVmed Inc
12/06/202414h05PR Newswire (US)4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
14/05/202402h43PR Newswire (US)PAVmed Provides Business Update and First Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
13/05/202414h00PR Newswire (US)Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
09/05/202413h49PR Newswire (US)Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA RecallNASDAQ:PAVMPAVmed Inc
07/05/202413h39PR Newswire (US)Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of DirectorsNASDAQ:PAVMPAVmed Inc
03/05/202414h35PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024NASDAQ:PAVMPAVmed Inc
02/05/202414h35PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024NASDAQ:PAVMPAVmed Inc
02/05/202413h49PR Newswire (US)Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
30/04/202413h35PR Newswire (US)PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteNASDAQ:PAVMPAVmed Inc
29/04/202414h47PR Newswire (US)Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthNASDAQ:PAVMPAVmed Inc
08/04/202414h30PR Newswire (US)Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PAVMPAVmed Inc
 Showing the most relevant articles for your search:NASDAQ:PAVM

Dernières Valeurs Consultées

EU
BE0002792738
Region Wallonne 1% until...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés